CommercialMay 1, 2021
Prior authorization updates for specialty pharmacy effective August 2021
Prior authorization updates
Effective for dates of service on and after August 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.
Please note, inclusion of national drug code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.
Visit our website to access the clinical criteria information.
Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM).
Clinical Criteria |
HCPCS or CPT Code(s) |
Drug |
**ING-CC-0186 |
J3490, J3590, J9999 |
Margenza |
*ING-CC-0187 |
J3490, J3590, J9999 |
Breyanzi |
*ING-CC-0188 |
J3490, J3590 |
Imcivree |
*ING-CC-0189 |
J3490, J3590, C9399 |
Amondys 45 |
*ING-CC-0190 |
J3490, J3590, C9399 |
Nulibry |
**ING-CC-0094 |
J9304 |
Pemfexy |
**ING-CC-0075 |
J3590, J9999, C9399 |
Riabni |
* Non-oncology use is managed by the medical specialty drug review team.
**Oncology use is managed by AIM.
Prior authorization coding update – change in clinical criteria
Effective August 18, 2020, these unclassified codes, J3490 and J3590, were removed from clinical criteria ING-CC-0072.
Quantity limit updates
Effective for dates of service on and after August 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.
Please note, inclusion of national drug code (NDC) code on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code.
Visit our website to access the clinical criteria information.
Prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology indications will be managed by AIM Specialty Health® (AIM), a separate company, and are shown in italics below.
Clinical Criteria |
HCPCS or CPT Code(s) |
Drug |
*ING-CC-0189 |
J3490, J3590, C9399 |
Amondys 45 |
*ING-CC-0190 |
J3490, J3590, C9399 |
Nulibry |
* Non-oncology use is managed by the medical specialty drug review team.
PUBLICATIONS: May 2021 Anthem Connecticut Provider News
To view this article online:
Or scan this QR code with your phone